FDA Guidance: Codevelopment of Two or More Unmarketed Investigational Drugs…
Combination therapy is an important treatment modality in many disease settings, including cancer, cardio-vascular disease, and…
Monthly Publications
In Depth
Subscribe Now
In Depth
coverage of timely
Life Science
Compliance issues
Subscribe Now
Governor Patrick to Reconsider Massachusetts Code of Conduct
A recent article discussed the approach Massachusetts Governor Deval Patrick has taken for engaging business and economic…
FDA Guidance for Industry on Medication Guides
The Food and Drug Administration (FDA) recently published Guidance for Industry on Medication Guides, entitled “Distribution…
University Policy: Duke and UNC Consider Revising Policies on Collaboration…
The Duke University School of Medicine presently has a policy regarding relationships with industry that requires faculty to…
University Policies Make Them Easier or Harder?
Earlier this year, we noted that the University of Colorado Medical Campus, National Jewish and Denver Health, were considering…
Pharmaceutical Coupons A Health Choice
One of the biggest challenges facing health care reform is how to control health care costs while maintaining a high quality of…
Maryland “Gift Ban”: HB 818 Manufacturers of Prescribed Products –…
Last week, the Maryland House of Delegates Government Operations Subcommittee held a hearing on HB 818, known as the Manufacturers…
HHS-OIG: CMS-FDA Drug Registration and Listing Systems In Need of Update
The Centers for Medicare and Medicaid (CMS) is America’s largest healthcare payer, covering the costs for hospital and physician…
ABMS MOC CME White Paper: SACME and CMSS Responses
In response to the American Board of Medical Specialties (ABMS) White paper on CME for Maintenance of Certification (MOC), the…
Alliance for CME Social Media Best Practice Guidelines
The Alliance for CME (Alliance) recently decided to establish a formal presence in a variety of social media channels as part of…